Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261

Clinical Development of First-in-class Innate IO Agents


Masoud Tavazoie

Masoud Tavazoie

Masoud Tavazoie, Rgenix CEO and Co-Founder speaks at Immuno-Oncology 360°

From February 26th – 28th 2020, the sixth IO360 conference in New York City gathers key representatives from industry, non-profits, regulatory bodies, investors and patients to discuss advances and challenges in immuno-oncology (IO) in the fight against cancer. Stakeholders will present and contrast strategies in IO from a scientific, clinical and regulatory viewpoint. In spite of the immeasurable positive impact that IO has had for patients, recent failures of multiple agents suggest that in order to advance the field, new angles are required in the investigation of immunology and disease biology.

Masoud Tavazoie, CEO of RGENIX, will present rationale and development strategies for novel modalities impacting the innate immune system. These first or best in class molecules target myeloid derived suppressor cells and macrophages and represent new strategies to overcome resistance or to improve response to IO- and chemotherapy and achieve a more durable benefit for more patients.